Company Description
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism.
It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.
The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room.
LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
| Country | United States |
| Founded | 2004 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 130 |
| CEO | Nicholas Curtis |
Contact Details
Address: 2800 Discovery Drive Orlando, Florida 32826 United States | |
| Phone | 888 536 7271 |
| Website | lensar.com |
Stock Details
| Ticker Symbol | LNSR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001320350 |
| CUSIP Number | 52634L108 |
| ISIN Number | US52634L1089 |
| Employer ID | 32-0125724 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Nicholas T. Curtis | President, Chief Executive Officer and Director |
| Thomas R. Staab II, CPA | Chief Financial Officer and Secretary |
| Alan B. Connaughton | Chief Operating Officer |
| Kendra W. Wong | Principal Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 8, 2024 | 10-Q | Quarterly Report |
| Aug 8, 2024 | 8-K | Current Report |
| May 13, 2024 | 8-K | Current Report |
| May 9, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | 8-K | Current Report |
| May 8, 2024 | 8-K | Current Report |
| Mar 25, 2024 | ARS | Filing |
| Mar 25, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 25, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 5, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |